FDA Inspection
Novo Nordisk A/SNovo Nordisk A/S – FDA Inspection, Feb 8, 2017
Record Details
This FDA Inspection record concerns Novo Nordisk A/S, with an inspection on February 8, 2017, issued by the Center for Biologics Evaluation and Research, covering biologics.
- Person
- Omotunde O. Osunsanmi (Issuing Officer)
View Company Profile
ID · f7c9c747-d7de-4a6c-9886-e185d08b2706
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1007260
- FDA center
- Biologics
- Project area
- Blood and Blood Products
- Outcome
- Form 483 issued
Other FDA inspections of Novo Nordisk A/S
8| Date | Classification | Office | Project area |
|---|---|---|---|
| March 29, 2023 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| December 5, 2019 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| May 18, 2018 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| April 8, 2016 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| September 3, 2013 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Novo Nordisk A/S
- FDA Inspection 1245306 - 2023-03-29
- FDA Inspection 1165895 - 2019-12-05
- FDA Inspection 1057438 - 2018-05-18
- FDA Inspection 964462 - 2016-04-08
- FDA Inspection 846713 - 2013-09-03
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.